Other Events ·
GSK plc has announced that it will not progress further development of camlipixant in refractory chronic cough (RCC)…
GSKGSK plc
GSK plc has announced that it will not progress further development of camlipixant in refractory chronic cough (RCC) following mixed results from phase III clinical trials CALM-1 and CALM-2. While CALM-1 met its primary endpoint with 50mg twice daily, CALM-2 failed to reach statistical significance for the same dose at week 24, and the 25mg dose showed no significance in either study. GSK will continue to evaluate camlipixant in adults with irritable bowel syndrome (IBS-D and IBS-M) via the phase IIb BALANCE trial. GSK is a global biopharma company focused on disease prevention and treatment.